poisar

Stocks · News reference

8-K filing — Gain Therapeutics, Inc. (GANX)

SEC EDGARSEC EDGAR

Filed: 2026-07-16 AccNo: 0001104659-26-084086 Size: 193 KB Item 8.01: Other Events

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaBenzinga Newsdesk

    Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate

    Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 42.11 percent increase over losses of $(0.19) per share